EAACI biologicals guidelines-omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Agache, Ioana
• dc.contributor.author Akdis, Cezmi A.
• dc.contributor.author Akdis, Mubeccel
• dc.contributor.author Brockow, Knut
• dc.contributor.author Chivato, Tomas
• dc.contributor.author Del Giacco, Stefano
• dc.contributor.author Eiwegger, Thomas
• dc.contributor.author Eyerich, Kilian
• dc.contributor.author Giménez Arnau, Anna Maria
• dc.contributor.author Gutermuth, Jan
• dc.contributor.author Guttman-Yassky, Emma
• dc.contributor.author Maurer, Marcus
• dc.contributor.author Ogg, Graham
• dc.contributor.author Ong, Peck Y.
• dc.contributor.author O'Mahony, Liam
• dc.contributor.author Schwarze, Jürgen
• dc.contributor.author Warner, Amena
• dc.contributor.author Werfel, Thomas
• dc.contributor.author Palomares, Oscar
• dc.contributor.author Jutel, Marek
• dc.date.accessioned 2022-05-05T07:40:56Z
• dc.date.available 2022-05-05T07:40:56Z
• dc.date.issued 2022
• dc.description.abstract Chronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H1 R-antihistamines. Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness still require further clarification. The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed.
• dc.format.mimetype application/pdf
• dc.identifier.citation Agache I, Akdis CA, Akdis M, Brockow K, Chivato T, Del Giacco S, et al. EAACI biologicals guidelines-omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old. Allergy. 2022 Jan; 77(1): 17-38. DOI: 10.1111/all.15030
• dc.identifier.doi http://dx.doi.org/10.1111/all.15030
• dc.identifier.issn 0105-4538
• dc.identifier.uri http://hdl.handle.net/10230/52990
• dc.language.iso eng
• dc.publisher Wiley
• dc.rights This is the peer reviewed version of the following article: Agache I, Akdis CA, Akdis M, Brockow K, Chivato T, Del Giacco S, et al. EAACI biologicals guidelines-omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old. Allergy. 2022 Jan; 77(1): 17-38, which has been published in final form at http://dx.doi.org/10.1111/all.15030. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.subject.keyword GRADE
• dc.subject.keyword Chronic spontaneous urticaria
• dc.subject.keyword Guidelines
• dc.subject.keyword Omalizumab
• dc.title EAACI biologicals guidelines-omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/acceptedVersion